key: cord-0932747-cj4usx12 authors: Uusalo, Panu; Valtonen, Mika; Järvisalo, Mikko J. title: Hemodynamic and respiratory effects of dexmedetomidine sedation in critically ill Covid‐19 patients: A retrospective cohort study date: 2021-08-22 journal: Acta Anaesthesiol Scand DOI: 10.1111/aas.13970 sha: 8860b6536b798699b601c831f99bbf505c4e1db5 doc_id: 932747 cord_uid: cj4usx12 INTRODUCTION: Dexmedetomidine has been suggested to be a promising sedative for patients with Covid‐19 infection (CV19). However, use of dexmedetomidine is limited by its heart rate (HR) and arterial blood pressure lowering effects. Moreover, CV19 is associated with cardiac manifestations including bradyarrythmias. The hemodynamic effects of dexmedetomidine have not been previously studied in CV19 patients. We evaluated the effects of dexmedetomidine on hemodynamic and respiratory parameters of CV19 patients. METHODS: In this single center study, all CV19 patients receiving dexmedetomidine for sedation during a one year period were included. Our primary outcomes included changes in HR, mean arterial pressure (MAP), respiratory rate (RR), partial oxygen pressure of arterial blood/fraction of inspired oxygen‐ratio (PF‐ratio), and Richmond Agitation and Sedation Score (RASS) during dexmedetomidine administration. RESULTS: We identified 39 patients with a mean (SD) age of 58.3 (12.7) years. After initiation of dexmedetomidine, HR decreased by 16.9 (3.3) beats/min (95% CI 9.5–22.4; p < 0.001). During the 12‐hour follow‐up period, HR decrease was significant at 2 to 12 h. Incident bradycardia (<45/min) was reported in 12 (30.8%) patients and it was associated with lower plasma C‐reactive protein, Pro‐calcitonin, and troponin T levels. There was no change in MAP compared to baseline. Dexmedetomidine administration was associated with improvement of PF‐ratio (p < 0.001) and with decrease of RASS (p = 0.004). CONCLUSIONS: Dexmedetomidine is an effective sedative for CV19 patients and may improve their oxygenation. However, dexmedetomidine administration is associated with marked decline in HR and with a high incidence of bradycardia in patients with CV19. Patients admitted to intensive care unit (ICU) for the Covid-19 infection (CV19) usually require sedation to facilitate their respiratory work and ventilatory support. Most available sedative drugs carry a risk for adverse reactions including respiratory depression, confusion, and circulatory depression, which may be harmful or even lifethreatening to the patient. [1] [2] [3] [4] Dexmedetomidine is a relatively recent alpha-2-adrenoceptor activating drug registered for sedation in adult ICU patients. It may be used as an anesthetic adjunct in intubated patients, but also for light sedation in awake, spontaneously breathing patients with or without noninvasive ventilation. 5 In addition to its sedative effect, dexmedetomidine has analgesic and antiemetic effects. 6, 7 Compared to traditional sedatives and anesthetics, dexmedetomidine has very little effect on respiration, which makes it an ideal sedative for respiratory compromised spontaneously breathing patients. 8 Furthermore, dexmedetomidine has been shown to carry both cytoprotective and anti-inflammatory properties. 9 Dexmedetomidine has been suggested to be a promising sedative for CV19 patients 10 and to potentially attenuate the uncontrolled CV19-associated inflammatory response. 11 However, the use of dexmedetomidine is limited by its heart rate and blood pressure lowering effects, which preclude its use in many critically ill patients. 12 Moreover, patients with CV19 show a high incidence of cardiac manifestations including bradyarrhythmias. 13, 14 Current data on the hemodynamic effects of dexmedetomidine in CV19 patients is scarce and limited to case reports. 15, 16 The aim of this study was to evaluate hemodynamics and respiratory parameters in critically ill CV19 patients receiving dexmedetomidine sedation. Our hypothesis was that CV19 patients may benefit from dexmedetomidine use, but in some patients, a decrease in heart rate may prevent its use. Furthermore, we aimed to study the incidence of bradycardia and associated risk factors in CV19 patients receiving dexmedetomidine. We retrospectively identified all patients admitted to the ICU of Turku University Hospital (Turku, Finland) between March 2020 and March 2021 due to CV19 infection (ICD-10 codes U07.1 and U07.2). All patients with an age of 18 to 80 years, confirmed CV19 infection and requiring dexmedetomidine sedation for at least 12 consecutive hours during their ICU stay were included in the analysis. Patients in whom dexmedetomidine was stopped due to bradycardia within 12 h were also included. Patients with suspected but not proven CV19 infection and patients with ICU stay of less than 24 h were excluded from the analysis. Eligible patients were identified, and patient data were retrieved from the patient database of Turku University Hospital, Finland. Dexmedetomidine hydrochloride (100 mcg/ml) was diluted in NaCl 0.9% and administered as an intravenous (4 mcg/kg) infusion with a rate of 0.2-1.4 mcg/kg/h according to a prescription by the attending physician. Patients received other sedatives and analgesic opioids according to standard clinical practice. The depth of sedation was defined depending on the clinical situation of each patient, severity of respiratory failure and potential presence of patientventilator dyssynchrony. Norepinephrine was initiated in patients with hypotension (MAP <65 mmHg) and discontinuated if MAP remained above 65 mmHg over an hour with a norepinephrine infusion rate of 0.005 mcg/kg/min. Hemodynamic effects of dexmedetomidine were assessed by recording heart rate (HR), mean arterial pressure (MAP), vasoactive requirement, and cardiac rhythm. Respiratory effects of dexmedetomidine were assessed by recording the ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PF) and respiratory rate (RR). Restlessness and the depth of sedation were assessed by recording the Richmond Agitation and Sedation Scale (RASS). We recorded HR, MAP, PF, RR, RASS, vasoactive requirement, and heart rhythm before dexmedetomidine administration and at two-hour intervals up to 12 h after the initiation of dexmedetomidine infusion. A heart rate below 45/min was considered as significant bradycardia. To assess the potential effects of laboratory values on the hemodynamic effects of dexmedetomidine, we recorded blood hemoglobin, plasma, creatinine, c-reactive protein, procalcitonin, ferritin, sodium, potassium, and interleukin-6 at start of dexmedetomidine, and peak Dexmedetomidine is a frequently used sedative and anxiolytic in critically ill patients. This analysis shows that dexmedetomidine administration in critically ill patients with COVID-19 was associated with improved oxygenation but a marked decline in heart rate and a high incidence of bradycardia, which was associated to lower plasma C-reactive protein, pro-calcitonin, and troponin T levels. troponin T within 5 days before and after initiation of dexmedetomidine sedation. Primary outcomes of this study were changes in heart rate, mean arterial pressure, norepinephrine requirement, Richmond Agitation and Sedation Score, and PaO 2 /FiO 2 ratio. Secondary outcomes of the study were factors associated to incident bradycardia. Results are expressed as mean values with standard deviations (SD) for normally distributed variables, and as medians with interquartile ranges (IQR) when the normality assumption was not met. The Shapiro-Wilks test (p > 0.05) was used to assess normality assumptions. Table 1 . Apart from early discontinuation of dexmedetomidine due to severe bradycardia, total duration of dexmedetomidine sedation ranged in our study patients from 12 hours to three weeks. During the 12-hour observation period after initiation of dexmedetomidine infusion, HR decreased by 15.9 (3.3) beats/min (95% CI 9.5-22.4 beats/min; p < 0.001) and was significantly lower at 2 to 12 hours (p ≤ 0.01 for all comparisons) compared to baseline values (Table 2, Figure 1 ). Dexmedetomidine was discontinued in two patients after 3-and 4-hour infusion, respectively, due to severe bradyarrhythmia. None of the study patients developed a 2nd or 3rd degree atrioventricular block. All patients were in sinus rhythm throughout the study period. In the whole, cohort MAP remained PF-ratio at initiation of dexmedetomidine a,d 17.2±5.6 Hourly urine output (ml/kg/h) b,d 1.0 (0.7-1.9) Data are shown as mean and standard deviation or as median and interquartile range. Bpm, beats per minute; PaO 2 /FiO 2 , ratio of arterial oxygen partial pressure/fraction of inspired oxygen; RASS, richmond agitation and sedation score. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to baseline. Heart rate (beats per min) before and 12 h after initiation of intravenous dexmedetomidine (*p < 0.05) F I G U R E 2 Mean arterial pressure before and 12 h after initiation of intravenous dexmedetomidine unchanged compared to the baseline ( (Table S1 ). RR remained unchanged from the baseline during the five-hour observation period (p > 0.20 for all comparisons). (Table 2, Figure 5 ) RASS was significantly lower at 6 to 12 h compared to the baseline. (Table 2, Figure 6 ). This study is the first to examine the effects of dexmedetomidine sedation on hemodynamics and respiration of critically ill CV19 patients. Our results show that dexmedetomidine administration is associated with ameliorated oxygenation in critically ill patients with CV19. However, a concurrent marked decline in heart rate and a high incidence of bradycardia were observed during dexmedetomidine infusion. Incident bradycardia was associated with lower plasma Creactive protein, Pro-calcitonin, and troponin T levels. Apart from early discontinuation of dexmedetomidine in two patients with severe bradycardia, duration of dexmedetomidine seda- Values are mean ± SD or median (IQR) and given at initiation of dexmedetomidine infusion, unless stated otherwise. Abbreviations: ALAT, alanine amino transferase; BMI, body mass index; bpm, beats per minute; BUN, blood urea nitrogen; IL-6, interleukin-6; INR, international number ratio; MV, mechanical ventilation; NE, norepinephrine; NIV, noninvasive ventilation; PaO 2 /FiO 2 , ratio of arterial oxygen partial pressure/fraction of inspired oxygen; SAPS-II, simplified acute physiology score II; SOFA, sequential organ failure assessment. a During the 12 h period following initiation of dexmedetomidine infusion. Parameters during 12 h dexmedetomidine infusion by bradycardia (Heart rate <45/min) treated in ICUs. Interestingly, we also found that our patients had unusually low median severity of illness scores (SOFA, SAPS II, CCI; However, hemodynamic effects of dexmedetomidine may limit its use outside the ICU. With clinically used concentrations, heart rate typically decreases 15-20% from the baseline value in healthy volunteers. 8, 19 While hemodynamic effects of dexmedetomidine are usually well tolerated in healthy volunteers and in patients undergoing surgery, they may be detrimental to critically ill patients. Our study showed that initiation of dexmedetomidine infusion did not have a significant effect on MAP or vasoactive requirement, but heart rate decreased over 20% from the baseline. MAP even appeared to increase slightly after initiation of dexmedetomidine, despite there was no significant change compared to the baseline. In healthy volunteers, dexmedetomidine has a biphasic effect on blood pressure, since it decreases heart rate and cardiac output by centrally mediated sympatholysis, but in the same time increases vascular resistance by peripherally mediated vasoconstriction. 8 It has also been shown in critically ill that compared to propofol, sedation with dexmedeto- T and these biochemical markers were also inversely associated with bradycardia in logistic regression analyzes. The potential mechanism(s) responsible for this finding remain unclear, but it seems evident that dexmedetomidine-associated bradycardia is not a result of the upregulated inflammation response or cardiac involvement in CV19. It has been shown that dexmedetomidine reduces sympathetic tone and catecholamine levels in plasma. 24 In subjects with severe infection, plasma catecholamine levels are often increased, 25 which may partly explain the lower incidence of bradycardia in patients with higher CRP. Similarly, high sympathetic tone may increase cardiac work and myocardial oxygen consumption leading to elevations in Troponin T. 26 A recent study evaluated the effectiveness of dexmedetomidine combined with high flow nasal oxygen and long periods of awake prone positioning in ICU patients with moderate or severe CV19 pneumonia. 27 The study found that dexmedetomidine was satisfactory for CV19 patients with moderate or severe ARDS treated with high flow nasal cannula facilitating the acceptance of long periods of awake prone positioning. However, the study lacked a control intervention. Comparative studies on the use of dexmedetomidine and other sedatives in treatment of CV19 patients are warranted. Delirium has been shown to be common and associated with mortality in patients hospitalized with CV19. 28, 29 Effects of dexmedetomidine on delirium in ICU patients has been studied extensively and many studies have shown that dexmedetomidine may reduce the risk of delirium compared to other sedatives. 5, 30 There is also evidence that dexmedetomidine may reduce the duration of mechanical ventilation and ICU stay, but on the other hand hemodynamic effects of dexmedetomidine limit its use and may even increase the risk for adverse events. 28 The antidelirium effect of dexmedetomidine in CV19 patients remains to be evaluated. Strengths of this study include reliable and highly available data. To conclude, dexmedetomidine is an effective sedative agent for critically ill CV19 patients and may improve their oxygenation. However, use of dexmedetomidine is associated with a marked decline in heart rate and a high incidence of bradycardia in patients with CV19. Bradycardia appears to be associated to lower levels of inflammation markers and Troponin T levels. For this retrospective, register-based study, the regulatory review board waived the need for informed consent in terms of data collection and analysis and publication of results. For this retrospective, register-based study, the regulatory review board waived the need for informed consent in terms of data collection and analysis and publication of results. Challenges in sedation management in critically Ill patients with COVID-19: a brief review Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study Adverse hemodynamic events associated with concomitant dexmedetomidine and propofol for sedation in mechanically ventilated ICU patients Sedation options for the morbidly obese intensive care unit patient: a concise survey and an agenda for development Safety and efficacy of dexmedetomidine in acutely Ill adults requiring noninvasive ventilation: a systematic review and meta-analysis of randomized trials Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials Efficacy of dexmedetomidine on postoperative nausea and vomiting: a meta-analysis of randomized controlled trials The effects of increasing plasma concentrations of dexmedetomidine in humans Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis Dexmedetomidine: another arrow in the quiver to fight COVID-19 in intensive care units Potential therapeutic value of dexmedetomidine in COVID-19 patients admitted to ICU Risk factors for dexmedetomidine-associated hemodynamic instability in noncardiac intensive care unit patients Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumonia Bradycardia in patients with COVID-19: a calm before the storm? Medication unmasked Brugada syndrome and cardiac arrest in a COVID-19 patient A comparative study on clinical effects of dexmedetomidine and midazolam on patients with severe coronavirus disease 2019 on non-invasive ventilation Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019 Analysis of Critical care severity of illness scoring systems in patients with coronavirus disease 2019: a retrospective analysis of three U.K. ICUs Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile The effect of propofol and dexmedetomidine sedation on norepinephrine requirements in septic shock patients: a crossover trial Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in in vitro and in vivo models of sepsis Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice Dexmedetomidine-mediated prevention of renal ischemia-reperfusion injury depends in part on cholinergic anti-inflammatory mechanisms Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers Arterial norepinephrine changes in patients with septic shock Troponin elevation in coronary vs. non-coronary disease Effectiveness of dexmedetomidine combined with high flow nasal oxygen and long periods of awake prone positioning in moderate or severe COVID-19 pneumonia Delirium is common in patients hospitalized with COVID-19 Delirium and mortality in coronavirus disease 2019 (COVID-19) -a systematic review and meta-analysis Effect of dexmedetomidine on delirium during sedation in adult patients in intensive care units: a systematic review and meta-analysis Hemodynamic and respiratory effects of dexmedetomidine sedation in critically ill Covid-19 patients: A retrospective cohort study